Screener
Supernus Pharmaceuticals SUPN Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net cash provided by (used in) financing activities | 9,115 | (21,399) |
| Net change in cash, cash equivalents, and restricted cash | 56,421 | 46,517 |
| Cash and cash equivalents at beginning of year | 129,898 | 69,331 |
| Cash, cash equivalents, and restricted cash at end of year | $186,319 | $115,848 |
| Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets | ||
| Cash and cash equivalents | $184,869 | $115,848 |
| Restricted cash | 1,450 | — |
| Total cash, cash equivalents, and restricted cash shown in the statement of cash flows | $186,319 | $115,848 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's cash & equivalents?
- Supernus Pharmaceuticals (SUPN) reported cash & equivalents of $186.32M in Q1 2026.
- How has Supernus Pharmaceuticals's cash & equivalents changed year-over-year?
- Supernus Pharmaceuticals's cash & equivalents increased by 60.8% year-over-year, from $115.85M to $186.32M.
- What is the long-term trend for Supernus Pharmaceuticals's cash & equivalents?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's cash & equivalents has grown at a -14.8% compound annual growth rate (CAGR), from $288.64M to $129.9M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Supernus Pharmaceuticals's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude